- Transaxillary transcatheter aortic valve implantation (TAVI) as valve-in-valve procedure due to degeneration of an aortic bioprosthesis
- A chronic total occlusion (CTO) of ostial LAD in a young patient
- Percutaneous LAA closure in an elderly woman with contra-indication to oral anticoagulant therapy
- Antithrombotic strategy during PCI: challenging situations
- Multivessel disease and cardiac arrest
- A Large Atrial Septal Defect in a 59 year old male patient
- Renal Denervation - A Patient with Initial Response to Radiofrequency RDN and Recurrence of Uncontrolled Hypertension
Antoine GOMMEAUX – September 27, 2014
“Be sûre to Well déploied the device. ..before to retry the filter. Oct or i vus are nécessary. ....”
Oddir Jauregui – September 25, 2014
“I think in this case the option of Watchman or ACP is a real indication , and I have two...”
azhar mahmood kayani – September 21, 2014
“how frequently you have problem of pulling out jailed wire in BVS implantations”
Gulnur Kerimkulova – September 3, 2014
“I think? only recompensation by medication due to very high surgical risk with a logistics euroSc...”
Nicolas Boudou and Pamela Gatto – September 1, 2014
“Dear All, Thank you for your comments. The recanalization of a chronic total occlusion in p...”
Axxess™ Self-Expanding Bifurcation Drug-Eluting Stent Shown To Be Safe And Effective Up To Three Years
Paris, France, 19 May 2011 . New long-term data from the DIVERGE study, presented yesterday at EuroPCR 2011, showed that the use of the AxxessTM DES for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a three-year period. AxxessTM is a self-expanding bifurcation stent which releases Biolimus A9TM from an abluminal biodegradable polymer coating.
DIVERGE, a prospective, single-arm, multi-center study of 302 patients with de novo bifurcation lesions across 16 sites in Europe, Australia and New Zealand, is the largest study conducted to date with a DES specifically designed for treating coronary bifurcation lesions. Following implantation of Axxess, the sidebranch treatments were left at the operators' discretion. Additional conventional sirolimus-eluting stents (SES) were placed in 21.7% of the distal parent and/or side branch vessels. In 64.7% of the cases both branches were treated with an additional SES.
At three years post-procedure, the cumulative rate of MACE (a composite of cardiac death, MI and ischemia-driven TLR) was 16.3%. The occurrences of the individual components were 2.0% for cardiac death, 7.5% for myocardial infarction and 10.2% for ischemia-driven TLR.
There were only three cases (1.0%) of definite VLST (Very Late Stent Thrombosis), all of which involved at least one SES: however, just one of these cases also involved AxxessTM
"These long-term results from DIVERGE are important because of the frequent presentation of bifurcation lesions in our daily clinical practice," commented Principal Investigator Dr. Stefan Verheye, Middelheim Hospital, Antwerp, Belgium. "These types of lesions are associated with higher complication and restenosis rates compared to conventional lesions. The three-year results confirm the earlier results already presented, and strengthen the evidence that the Axxess stent is a safe and effective alternative for patients with certain bifurcation lesions."
The Axxess bifurcation DES consists of a self-expanding, conically-shaped Nitinol (nickel/titanium) stent platform, specifically designed to conform to the shape of the bifurcation anatomy. It supports the carina while preserving the side branch. The Axxess stent is abluminally coated with a biodegradable poly-lactic acid (PLA) polymer that releases Biolimus A9TM (BA9TM), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. BA9 is a vital component of
the BioMatrix FlexTM DES system, which has been proven safe and effective in the landmark "all-comers" LEADERS study.
Biosensors received CE Mark approval for the Axxess bifurcation DES in April 2011, supported by the positive nine-month results from the DIVERGE trial, which were published in the Journal of the American College of Cardiology (JACC) in March 2009. These demonstrated low overall rates of MACE (7.6%), restenosis (0.7%) and late stent thrombosis (0.3%) in patients treated with Axxess.
Biosensors expects to make the Axxess bifurcation DES available later this year. The device will be manufactured in diameters of 3.0 mm and 3.5 mm, and lengths of 11 mm and 14 mm.
About Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.
With the increasing use of the BioMatrix. family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The forthcoming launch of the AxxessTM self-expanding bifurcation drug-eluting stent and the development of the BioFreedom. drug-coated stent will further reinforce our market position.
All three stents incorporate Biolimus A9TM (BA9TM), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9TM The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9TM, is currently undergoing clinical evaluation.
For more information, please visit www.biosensors.com (You will be visiting a website outside of PCRonline, we are not responsible for its contents).
Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forwardlooking terminology, such as "may","will","expect","intend","estimate, "anticipate","believe","project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.